Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552085 | 0.92 | ALDH1A1 (0.35) | EGLN1MAOBKDM4EALDH1A1GAA | |
| SCHEMBL5557571 | 0.78 | KDM4E (0.43) | MAOBKDM4EALDH1A1GAAHPGD | |
| SCHEMBL5551651 | 0.74 | L3MBTL1 (0.38) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL5555815 | 0.73 | HPGD (0.35) | MAOBKDM4EALDH1A1GAAHPGD | |
| Bicarbonate SCHEMBL5276729 | 0.72 | GAA (0.39) | EGLN1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL5555926 | 0.72 | PTPN1 (0.37) | MAOBKDM4EGAA | |
| SCHEMBL5276727 | 0.71 | MAPT (0.44) | ALDH1A1NPSR1 | |
| SCHEMBL5272450 | 0.71 | PTPN1 (0.39) | KDM4E | |
| SCHEMBL5276721 | 0.71 | ALDH1A1 (0.37) | EGLN1MAOBKDM4EALDH1A1GAA | |
| SCHEMBL5279556 | 0.71 | NPSR1 (0.47) | KDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070003484-A1 | Hydroxypyridinone derivatives, metal complexes thereof and the use thereof for preparing conjugates with biomolecules | SCHERING AG (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20060292079-A1 | Conjugates of hydroxypyridinone derivative metal complexes with biomolecules and their use for MRI diagnosis | EPIX PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292079-A1 | Conjugates of hydroxypyridinone derivative metal complexes with biomolecules and their use for MRI diagnosis | KLK3, HPGD, HAMP | EGLN1 889/4885MAOB 1941/4885KDM4E 1907/4885 |
| US-20070003484-A1 | Hydroxypyridinone derivatives, metal complexes thereof and the use thereof for preparing conjugates with biomolecules | HPD, HAMP, KLK3 | EGLN1 921/4885MAOB 2771/4885KDM4E 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.